The relationship between serum oxalic acid, central hemodynamic parameters and colonization by oxalobacter formigenes in hemodialysis patients

CardioRenal Medicine

Volumn 5, Issue 3, 2015, Pages 164-174

  Gulhan, Baris ^a   Turkmen, Kultigin ^b   Aydin, Merve ^a   Gunay, Murat ^a   Cikman, Aytekin ^a   Kara, Murat ^a  

^a ERZINCAN UNIVERSITY   (Turkey)

^b NECMETTIN ERBAKAN UNIVERSITY   (Turkey)

Author keywords

Central aortic blood pressures; Colo reno cardiac axis; Oxalic acid; Oxalobacter formigenes; Pulse wave velocity

Indexed keywords

LOW DENSITY LIPOPROTEIN; OXALIC ACID; PREBIOTIC AGENT; PROBIOTIC AGENT;

ADULT; AGED; AORTA PRESSURE; ARTICLE; BACTERIAL COLONIZATION; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR MORTALITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DNA ISOLATION; FEMALE; HEMODIALYSIS PATIENT; HEMODYNAMIC PARAMETERS; HOMEOSTASIS; HUMAN; MALE; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; OXALOBACTER FORMIGENES; PATHOGENESIS; PRIORITY JOURNAL; PULSE WAVE; REAL TIME POLYMERASE CHAIN REACTION;

EID: 84930892899     PISSN: 16643828     EISSN: 16645502     Source Type: Journal    
DOI: 10.1159/000381219     Document Type: Article

References (41)

1. Collins AJ: Cardiovascular mortality in end-stage renal disease. Am J Med Sci 2003; 325: 163-167.
2. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, et al: Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009; 302: 1782-1789.
3. Evenepoel P, Meijers BK, Bammens BR, Verbeke K: Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl 2009; 114:S12-S19.
4. Meijers BK, Evenepoel P: The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol Dial Transplant 2011; 26: 759-761.
5. Meijers B, Toussaint ND, Meyer T, Bammens B, Verbeke K, Vanrenterghem Y, et al: Reduction in proteinbound solutes unacceptable as marker of dialysis efficacy during alternate-night nocturnal hemodialysis. Am J Nephrol 2011; 34: 226-232.
6. Goldfarb DS, Modersitzki F, Asplin JR: A randomized, controlled trial of lactic acid bacteria for idiopathic hyperoxaluria. Clin J Am Soc Nephrol 2007; 2: 745-749.
7. Curhan GC: Epidemiology of stone disease. Urol Clin North Am 2007; 34: 287-293.
8. Kelly JP, Curhan GC, Cave DR, Anderson TE, Kaufman DW: Factors related to colonization with Oxalobacter formigenes in US adults. J Endourol 2011; 25: 673-679.
9. Ferraro PM, Taylor EN, Gambaro G, Curhan GC: Soda and other beverages and the risk of kidney stones. Clin J Am Soc Nephrol 2013; 8: 1389-1395.
10. Turkmen K, Erdur FM: The relationship between colonization of Oxalobacter formigenes serum oxalic acid and endothelial dysfunction in hemodialysis patients: from impaired colon to impaired endothelium. Med Hypotheses 2015; 84: 273-275.
11. Chitalia N, Ismail T, Tooth L, Boa F, Hampson G, Goldsmith D, et al: Impact of vitamin D supplementation on arterial vasomotion, stiffness and endothelial biomarkers in chronic kidney disease patients. PLoS One 2014; 9:e91363.
12. Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, et al: Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 1995; 26: 485-490.
13. Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y: Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 1996; 74: 349-355.
14. Yasuda G, Shibata K, Takizawa T, Ikeda Y, Tokita Y, Umemura S, et al: Prevalence of constipation in continuous ambulatory peritoneal dialysis patients and comparison with hemodialysis patients. Am J Kidney Dis 2002; 39: 1292-1299.
15. Kalantar-Zadeh K, Kopple JD, Deepak S, Block D, Block G: Food intake characteristics of hemodialysis patients as obtained by food frequency questionnaire. J Ren Nutr 2002; 12: 17-31.
16. Wu MJ, Chang CS, Cheng CH, Chen CH, Lee WC, Hsu YH, et al: Colonic transit time in long-term dialysis patients. Am J Kidney Dis 2004; 44: 322-327.
17. Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P: Evidence for impaired assimilation of protein in chronic renal failure. Kidney Int 2003; 64: 2196-2203.
18. Hatch M, Cornelius J, Allison M, Sidhu H, Peck A, Freel RW: Oxalobacter sp reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int 2006; 69: 691-698.
19. Jiang Z, Asplin JR, Evan AP, Rajendran VM, Velazquez H, Nottoli TP, et al: Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. Nat Genet 2006; 38: 474-478.
20. Hatch M, Gjymishka A, Salido EC, Allison MJ, Freel RW: Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter . Am J Physiol Gastrointest Liver Physiol 2011; 300:G461-G469.
21. Hoppe B, Dittlich K, Fehrenbach H, Plum G, Beck BB: Reduction of plasma oxalate levels by oral application of Oxalobacter formigenes in 2 patients with infantile oxalosis. Am J Kidney Dis 2011; 58: 453-455.
22. Hatch M, Freel RW, Vaziri ND: Intestinal excretion of oxalate in chronic renal failure. J Am Soc Nephrol 1994; 5: 1339-1343.
23. Mogna L, Pane M, Nicola S, Raiteri E: Screening of different probiotic strains for their in vitro ability to metabolise oxalates: Any prospective use in humans? J Clin Gastroenterol 2014; 48(suppl 1):S91-S95.
24. Prokopovich S, Knight J, Assimos DG, Holmes RP: Variability of Oxalobacter formigenes and oxalate in stool samples. J Urol 2007; 178: 2186-2190.
25. Salminen S, Isolauri E, Salminen E: Clinical uses of probiotics for stabilizing the gut mucosal barrier: successful strains and future challenges. Antonie Van Leeuwenhoek 1996; 70: 347-358.
26. Otles S, Cagindi O, Akcicek E: Probiotics and health. Asian Pac J Cancer Prev 2003; 4: 369-372.
27. Nielsen B, Gurakan GC, Unlu G: Kefir: A multifaceted fermented dairy product. Probiotics Antimicrob Proteins 2014; 6: 123-135.
28. Garrote GL, Abraham AG, De Antoni GL: Chemical and microbiological characterisation of kefir grains. J Dairy Res 2001; 68: 639-652.
29. Marsh AJ, O'Sullivan O, Hill C, Ross RP, Cotter PD: Sequencing-based analysis of the bacterial and fungal composition of kefir grains and milks from multiple sources. PLoS One 2013; 8:e69371.
30. Zarrati M, Salehi E, Nourijelyani K, Mofid V, Zadeh MJ, Najafi F, et al: Effects of probiotic yogurt on fat distribution and gene expression of proinflammatory factors in peripheral blood mononuclear cells in overweight and obese people with or without weight-loss diet. J Am Coll Nutr 2014; 33: 417-425.
31. Poesen R, Viaene L, Verbeke K, Claes K, Bammens B, Sprangers B, et al: Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl sulfate in CKD. Clin J Am Soc Nephrol 2013; 8: 1508-1514.
32. Poesen R, Meijers B, Evenepoel P: The colon: An overlooked site for therapeutics in dialysis patients. Semin Dial 2013; 26: 323-332.
33. Protogerou AD, Papaioannou TG, Blacher J, Papamichael CM, Lekakis JP, Safar ME: Central blood pressures: do we need them in the management of cardiovascular disease? Is it a feasible therapeutic target? J Hypertens 2007; 25: 265-272.
34. Weir MR, Townsend RR, Fink JC, Teal V, Anderson C, Appel L, et al: Hemodynamic correlates of proteinuria in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 2403-2410.
35. Weiss W, Gohlisch C, Harsch-Gladisch C, Tolle M, Zidek W, van der Giet M: Oscillometric estimation of central blood pressure: validation of the Mobil-O-Graph in comparison with the SphygmoCor device. Blood Press Monit 2012; 17: 128-131.
36. Blacher J, Safar ME, Guerin AP, Pannier B, Marchais SJ, London GM: Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 2003; 63: 1852-1860.
37. Mydlik M, Derzsiova K: Oxalic acid-important uremic toxin (in Slovak). Vnitr Lek 2010; 56: 695-701.
38. France NC, Holland PT, Wallace MR: Contribution of dialysis to endogenous oxalate production in patients with chronic renal failure. Clin Chem 1994; 40: 1544-1548.
39. Costello JF, Sadovnic MJ, Cottington EM: Plasma oxalate levels rise in hemodialysis patients despite increased oxalate removal. J Am Soc Nephrol 1991; 1: 1289-1298.
40. Phan O, Ivanovski O, Nguyen-Khoa T, Mothu N, Angulo J, Westenfeld R, et al: Sevelamer prevents uremiaenhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 2005; 112: 2875-2882.
41. Brandenburg VM, Schlieper G, Heussen N, Holzmann S, Busch B, Evenepoel P, et al: Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: A prospective study. Nephrol Dial Transplant 2010; 25: 2672-2679.